SCHEMBL4498181

SCHEMBL4498181

O=Cc1ccc(N2CC(c3nc4c(cnn4-c4ccccc4)c(=O)[nH]3)C2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYK2 P29597 1/20 0.56
ALDH1A1 P00352 7/20 0.46
PDE5A O76074 4/20 0.46
TSHR P16473 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
HPGD P15428 2/20 0.46
TP53 P04637 1/20 0.46
KDM4E B2RXH2 2/20 0.46
LMNA P02545 2/20 0.46
GAA P10253 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HTT P42858 1/20 0.43
MAPK1 P28482 1/20 0.42
MAPT P10636 2/20 0.42
CREBBP Q92793 1/20 0.42
HSD17B10 Q99714 1/20 0.42
DAPK3 O43293 1/20 0.42
PIM1 P11309 1/20 0.42
PIM3 Q86V86 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4591180 0.92 TYK2 (0.62) TYK2ALDH1A1PDE5ATSHRL3MBTL1
SCHEMBL4510623 0.85 TYK2 (0.55) TYK2ALDH1A1PDE5ATSHRL3MBTL1
SCHEMBL17506173 0.84 TYK2 (0.57) TYK2ALDH1A1PDE5ATSHRL3MBTL1
SCHEMBL4498176 0.81 PDE9A (0.50) TYK2
SCHEMBL4502011 0.80 MAPK1 (0.50) TYK2ALDH1A1TSHRHPGDTP53
SCHEMBL4510202 0.80 TYK2 (0.58) TYK2ALDH1A1PDE5ATSHRL3MBTL1
SCHEMBL4504690 0.80 TYK2 (0.49) TYK2ALDH1A1PDE5ATSHRL3MBTL1
SCHEMBL4512357 0.79 KMT2A (0.53) TYK2ALDH1A1PDE5ATSHRL3MBTL1
Hydrochloric Acid SCHEMBL4511418 0.78 TYK2 (0.62) TYK2ALDH1A1PDE5ATSHRL3MBTL1
SCHEMBL4501740 0.78 ALDH1A1 (0.52) TYK2ALDH1A1PDE5ATSHRL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137549-A1 Novel compounds useful for the treatment of degenerative & inflamatory diseases GALAPAGOS NV (BE) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137549-A1 Novel compounds useful for the treatment of degenerative & inflamatory diseases PDE4A, PDE7B, PDE4B TYK2 3816/4885ALDH1A1 240/4885PDE5A 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.